Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects
about
Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesMRG15 regulates embryonic development and cell proliferation.System theoretical investigation of human epidermal growth factor receptor-mediated signalling.HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cellsIn vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells.Kaempferol Downregulates Insulin-like Growth Factor-I Receptor and ErbB3 Signaling in HT-29 Human Colon Cancer Cells.Reorienting the Fab domains of trastuzumab results in potent HER2 activators.Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological responseAnti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerCombining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerTargeting protein kinases in cancer therapy: a success?Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.Pertuzumab for the treatment of ovarian cancer.Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer.ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.Molecular modeling of nearly full-length ErbB2 receptor.Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells.Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.Challenging issues in molecular-targeted therapy.Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells.Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells.Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2.Binding of GRB2:GAB1 to p-ERBB2:p-EGFRBinding of PI3K to GRB2:GAB1 in complex with phosphorylated heterodimer of ERBB2 and EGFR.
P2860
Q24537669-A977D4E4-36A2-4CA3-85E4-5A781F712895Q26822730-F770D05A-78DA-4A7A-960B-3EBCB52F36EEQ28513444-73AE8D87-96C2-4E66-80AF-8C0DF905F0AAQ33388432-DE160F17-978A-4D25-9351-AA7BCA53929DQ33514127-69254ADE-71B1-4BAD-B902-B1507BA9E983Q33620124-31144778-3450-4C4C-A8B4-2B92BE062E8AQ33642507-C6937B78-A584-46AB-8973-4E190BEF9DECQ33758795-C66651E0-450A-44C9-8283-57830C412B07Q34305680-244C50E6-CD47-4B41-ABDC-359D4E59757DQ34532338-462194C8-5086-4449-BB30-9475FEF66C91Q34600838-8AE3DF6F-CC91-4AD4-84B3-71682A7CB048Q34659512-0007270C-CD19-4AD7-B4CF-39D17A3CDDE3Q34775370-D2CEB989-D829-40A1-A481-9E1F29702620Q35742383-A5912567-4CFE-48CF-8BBF-B3E3692ECD3FQ35987779-46E719B1-2106-4C17-BECD-3547CA201E81Q36311216-41AB64AE-72E0-4F7B-A767-A78625FA4D22Q36613598-A3AFEBC6-4C00-4655-8F89-A37FD4D5F61BQ36702442-05A15533-2C42-4945-9564-5105BB881844Q36943119-718CF15B-390A-426D-B1C3-AB07F98E9B38Q37273963-7642B4FD-7B0D-4E8E-9722-8B8085BCD055Q37694673-07FE77BA-6FBF-4C34-A8CA-356DB56F0058Q37699264-BDD371E7-07F4-4624-B072-7249BDFECF26Q37725973-9825EDA2-E971-4AE9-A165-D97CC0A6295EQ37750891-E0B94024-E689-43B0-952E-D6A5BA2E15A8Q38390565-BC160F77-6245-4BF4-844C-F387B8A700D4Q38867798-82A7E6DB-58DD-4708-85B8-54B21B83B88CQ38974852-670DCDE4-1108-49A6-8788-80C9280D2164Q39206148-C473DB51-4F85-42C1-A662-A7918B0AD713Q39882524-800AEDEC-F188-404F-849F-4FB4ED857FF9Q40040751-8634DDC9-2214-47C5-BC31-240D02BD3D7DQ40316579-9560F3E6-5247-4A37-8B51-1122500E5D16Q40423784-AA9C3796-1F7D-4A35-9319-7CC17D6DDC57Q40462593-A4030CF2-77D9-44D9-8C89-AF6D9C97F248Q40486229-995A3929-4D1B-4C62-A962-1A5D5D1864C7Q41436013-6FF3F35D-49AE-45F6-B56F-01FC16E11F1EQ42123911-6CB56286-D58D-431B-98F9-9D6AB5EB355CQ43088457-EEA5C1B8-7E9B-4CCD-A910-B4EC93B5E76AQ48455124-2C203015-473D-4A55-9C16-31A0A03E87E1Q50298007-EB7AB657-9100-4CEB-ADB9-5E58E423420EQ50298008-30506063-EC06-4EF5-A3C9-D91B96878026
P2860
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects
description
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im April 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2004/04/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/04/01)
@nl
наукова стаття, опублікована у квітні 2004
@uk
مقالة علمية (نشرت في أبريل 2004)
@ar
name
Blockade of epidermal growth f ...... m signaling and growth effects
@ast
Blockade of epidermal growth f ...... m signaling and growth effects
@en
Blockade of epidermal growth f ...... m signaling and growth effects
@nl
type
label
Blockade of epidermal growth f ...... m signaling and growth effects
@ast
Blockade of epidermal growth f ...... m signaling and growth effects
@en
Blockade of epidermal growth f ...... m signaling and growth effects
@nl
prefLabel
Blockade of epidermal growth f ...... m signaling and growth effects
@ast
Blockade of epidermal growth f ...... m signaling and growth effects
@en
Blockade of epidermal growth f ...... m signaling and growth effects
@nl
P2093
P1433
P1476
Blockade of epidermal growth f ...... m signaling and growth effects
@en
P2093
Mark X Sliwkowski
Michael G Brattain
Patricia St Clair
P304
P356
10.1158/0008-5472.CAN-03-3106
P407
P577
2004-04-01T00:00:00Z